Screener
Nektar Therapeutics NKTR Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssets.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Long-term prepaid research and development expenses | $2,757 | $4,244 |
| Operating lease right-of-use assets | 2,761 | 2,941 |
| Property and equipment, net | 1,959 | 2,060 |
| Equity method investment in Gannet BioChem | 1,741 | 3,491 |
| Other long-term assets | 2,019 | 1,404 |
| Total other assets | $11,237 | $14,140 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's other non-current assets?
- Nektar Therapeutics (NKTR) reported other non-current assets of $11.24M in Q1 2026.
- How has Nektar Therapeutics's other non-current assets changed year-over-year?
- Nektar Therapeutics's other non-current assets increased by 108.4% year-over-year, from $5.39M to $11.24M.
- What is the long-term trend for Nektar Therapeutics's other non-current assets?
- Over 5 years (2020 to 2025), Nektar Therapeutics's other non-current assets has grown at a 57.5% compound annual growth rate (CAGR), from $1.46M to $14.14M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Nektar Therapeutics's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude